Global Update 2026: Selumetinib (KOSELUGO) Expands Indication to Adult NF1-PN and Clinical Management Strategies

　　Between 2025 and 2026,Selumetinib Capsules(KOSELUGO)achieved significant regulatory milestones globally.The U.S.Food and Drug Administration(FDA)approved its use for adults aged 18 and older with symptomatic,inoperable plexiform neurofibromas(PN)associated with Neurofibromatosis Type 1(NF1).Published in The Lancet,this update bridges the treatment gap for adults,extending care beyond pediatric populations.Concurrently,health authorities in Canada and the EU aligned on these indications.

　　Selumetinib,a potent MEK1/2 inhibitor,targets the hyperactive RAS/MAPK pathway resulting from NF1 gene mutations.While effective in suppressing tumor proliferation,it does not correct the underlying genetic defect,necessitating continuous therapy to mitigate relapse risks.

　　The approval hinged on the KOMET Phase III trial(NCT04924608),involving 145 adults across 13 countries.Results demonstrated a statistically significant improvement in Objective Response Rate(ORR)compared to placebo,with 86%of responders maintaining reduction for over six months.Unlike the pediatric SPRINT trial which showed higher ORR,adult data primarily reflect disease stabilization,guiding realistic clinical expectations.

　　Dosing is strictly Body Surface Area(BSA)-dependent.The standard regimen is 25 mg/m²twice daily.Specific adjustments range from 20 mg to 50 mg per dose based on BSA tiers.For hepatic impairment,patients with moderate(Child-Pugh B)liver dysfunction require a reduction to 20 mg/m²twice daily;use in severe(Child-Pugh C)impairment is contraindicated due to insufficient safety data.

　　Regarding global availability,pricing varies significantly.While Western formulations command premium prices,versions manufactured in Southeast Asia offer a lower-cost alternative.Although containing the same active ingredient,these alternatives may differ in excipients and bioequivalence profiles and must be sourced through legitimate international channels.

　　Safety monitoring is paramount.Common adverse events include dermatologic toxicities(acneiform rash),gastrointestinal disturbances,and elevated creatine phosphokinase.Baseline and quarterly ophthalmic exams,cardiac function assessments(LVEF),and lab monitoring are mandatory.Permanent discontinuation is required for irreversible retinal toxicity or severe cardiomyopathy.

　　Clinical FAQs often address off-label scenarios.Use in toddlers under two years remains contentious due to limited long-term safety data and swallowing risks.Given embryotoxic potential,strict contraception is advised for all patients of reproductive potential.In conclusion,while not curative,Selumetinib remains a pivotal targeted therapy for managing NF1-PN progression and improving quality of life.